ARTICLE | Clinical News
Barrier's Hyphanox misses Phase III endpoint
June 30, 2005 1:33 AM UTC
BTRX said its Hyphanox itraconazole missed the primary endpoint of non-inferior therapeutic cure compared with fluconazole at day 25 in a Phase III trial to treat vaginal candidiasis. In the double-bl...